vs
IMMUCELL CORP（ICCC）与Lantheus Holdings, Inc.（LNTH）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是IMMUCELL CORP的73.9倍（$406.8M vs $5.5M）。Lantheus Holdings, Inc.净利率更高（13.3% vs -2.5%，领先15.8%）。Lantheus Holdings, Inc.同比增速更快（4.0% vs -8.4%）。Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $-1.8M）。过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs 3.9%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
ICCC vs LNTH — 直观对比
营收规模更大
LNTH
是对方的73.9倍
$5.5M
营收增速更快
LNTH
高出12.4%
-8.4%
净利率更高
LNTH
高出15.8%
-2.5%
自由现金流更多
LNTH
多$83.2M
$-1.8M
两年增速更快
LNTH
近两年复合增速
3.9%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $406.8M |
| 净利润 | $-139.7K | $54.1M |
| 毛利率 | 42.9% | 59.2% |
| 营业利润率 | 0.4% | 19.0% |
| 净利率 | -2.5% | 13.3% |
| 营收同比 | -8.4% | 4.0% |
| 净利润同比 | 80.1% | 558.8% |
| 每股收益（稀释后） | $-0.02 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCLNTH
| Q4 25 | — | $406.8M | ||
| Q3 25 | $5.5M | $384.0M | ||
| Q2 25 | $6.4M | $378.0M | ||
| Q1 25 | $8.1M | $372.8M | ||
| Q4 24 | $7.8M | $391.1M | ||
| Q3 24 | $6.0M | $378.7M | ||
| Q2 24 | $5.5M | $394.1M | ||
| Q1 24 | $7.3M | $370.0M |
净利润ICCCLNTH
| Q4 25 | — | $54.1M | ||
| Q3 25 | $-139.7K | $27.8M | ||
| Q2 25 | $501.9K | $78.8M | ||
| Q1 25 | $1.4M | $72.9M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | $-701.7K | $131.1M | ||
| Q2 24 | $-1.5M | $62.1M | ||
| Q1 24 | $-437.9K | $131.1M |
毛利率ICCCLNTH
| Q4 25 | — | 59.2% | ||
| Q3 25 | 42.9% | 57.9% | ||
| Q2 25 | 43.7% | 63.8% | ||
| Q1 25 | 41.6% | 63.8% | ||
| Q4 24 | 36.5% | 63.5% | ||
| Q3 24 | 26.3% | 63.9% | ||
| Q2 24 | 22.5% | 64.9% | ||
| Q1 24 | 31.6% | 65.4% |
营业利润率ICCCLNTH
| Q4 25 | — | 19.0% | ||
| Q3 25 | 0.4% | 11.4% | ||
| Q2 25 | 8.8% | 23.3% | ||
| Q1 25 | 13.9% | 27.4% | ||
| Q4 24 | 8.0% | 29.1% | ||
| Q3 24 | -9.6% | 35.3% | ||
| Q2 24 | -25.3% | 26.1% | ||
| Q1 24 | -4.1% | 28.8% |
净利率ICCCLNTH
| Q4 25 | — | 13.3% | ||
| Q3 25 | -2.5% | 7.2% | ||
| Q2 25 | 7.8% | 20.8% | ||
| Q1 25 | 17.9% | 19.6% | ||
| Q4 24 | — | -3.0% | ||
| Q3 24 | -11.7% | 34.6% | ||
| Q2 24 | -28.0% | 15.8% | ||
| Q1 24 | -6.0% | 35.4% |
每股收益（稀释后）ICCCLNTH
| Q4 25 | — | $0.86 | ||
| Q3 25 | $-0.02 | $0.41 | ||
| Q2 25 | $0.06 | $1.12 | ||
| Q1 25 | $0.16 | $1.02 | ||
| Q4 24 | $0.09 | $-0.18 | ||
| Q3 24 | $-0.09 | $1.79 | ||
| Q2 24 | $-0.20 | $0.88 | ||
| Q1 24 | $-0.06 | $1.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $359.1M |
| 总债务越低越好 | $9.5M | $568.7M |
| 股东权益账面价值 | $29.8M | $1.1B |
| 总资产 | $45.7M | $2.2B |
| 负债/权益比越低杠杆越低 | 0.32× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资ICCCLNTH
| Q4 25 | — | $359.1M | ||
| Q3 25 | $3.9M | $382.0M | ||
| Q2 25 | — | $695.6M | ||
| Q1 25 | — | $938.5M | ||
| Q4 24 | $3.8M | $912.8M | ||
| Q3 24 | — | $866.4M | ||
| Q2 24 | $1.3M | $757.0M | ||
| Q1 24 | $960.3K | $718.3M |
总债务ICCCLNTH
| Q4 25 | — | $568.7M | ||
| Q3 25 | $9.5M | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | $8.7M | $566.1M | ||
| Q4 24 | $9.0M | $565.3M | ||
| Q3 24 | $9.4M | $613.0K | ||
| Q2 24 | $9.8M | $563.2M | ||
| Q1 24 | $10.2M | $562.5M |
股东权益ICCCLNTH
| Q4 25 | — | $1.1B | ||
| Q3 25 | $29.8M | $1.1B | ||
| Q2 25 | $29.9M | $1.2B | ||
| Q1 25 | $29.0M | $1.2B | ||
| Q4 24 | $27.5M | $1.1B | ||
| Q3 24 | $26.4M | $1.2B | ||
| Q2 24 | $23.5M | $1.0B | ||
| Q1 24 | $24.6M | $945.5M |
总资产ICCCLNTH
| Q4 25 | — | $2.2B | ||
| Q3 25 | $45.7M | $2.3B | ||
| Q2 25 | $46.7M | $2.1B | ||
| Q1 25 | $45.6M | $2.1B | ||
| Q4 24 | $45.1M | $2.0B | ||
| Q3 24 | $44.4M | $2.0B | ||
| Q2 24 | $41.9M | $1.9B | ||
| Q1 24 | $43.1M | $1.8B |
负债/权益比ICCCLNTH
| Q4 25 | — | 0.52× | ||
| Q3 25 | 0.32× | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | 0.30× | 0.49× | ||
| Q4 24 | 0.33× | 0.52× | ||
| Q3 24 | 0.36× | 0.00× | ||
| Q2 24 | 0.42× | 0.55× | ||
| Q1 24 | 0.41× | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $90.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $81.4M |
| 自由现金流率自由现金流/营收 | -32.3% | 20.0% |
| 资本支出强度资本支出/营收 | 10.8% | 2.2% |
| 现金转化率经营现金流/净利润 | — | 1.67× |
| 过去12个月自由现金流最近4个季度 | $715.4K | $354.1M |
8季度趋势，按日历期对齐
经营现金流ICCCLNTH
| Q4 25 | — | $90.2M | ||
| Q3 25 | $-1.2M | $105.3M | ||
| Q2 25 | $1.6M | $87.1M | ||
| Q1 25 | $1.6M | $107.6M | ||
| Q4 24 | $-3.1K | $157.7M | ||
| Q3 24 | $-639.3K | $175.1M | ||
| Q2 24 | $581.8K | $84.7M | ||
| Q1 24 | $418.5K | $127.2M |
自由现金流ICCCLNTH
| Q4 25 | — | $81.4M | ||
| Q3 25 | $-1.8M | $94.7M | ||
| Q2 25 | $1.4M | $79.1M | ||
| Q1 25 | $1.2M | $98.8M | ||
| Q4 24 | $-199.3K | $141.4M | ||
| Q3 24 | $-727.7K | $159.3M | ||
| Q2 24 | $471.0K | $73.5M | ||
| Q1 24 | $348.1K | $119.0M |
自由现金流率ICCCLNTH
| Q4 25 | — | 20.0% | ||
| Q3 25 | -32.3% | 24.7% | ||
| Q2 25 | 22.4% | 20.9% | ||
| Q1 25 | 15.4% | 26.5% | ||
| Q4 24 | -2.6% | 36.1% | ||
| Q3 24 | -12.1% | 42.0% | ||
| Q2 24 | 8.6% | 18.7% | ||
| Q1 24 | 4.8% | 32.2% |
资本支出强度ICCCLNTH
| Q4 25 | — | 2.2% | ||
| Q3 25 | 10.8% | 2.8% | ||
| Q2 25 | 2.4% | 2.1% | ||
| Q1 25 | 4.1% | 2.3% | ||
| Q4 24 | 2.5% | 4.2% | ||
| Q3 24 | 1.5% | 4.2% | ||
| Q2 24 | 2.0% | 2.8% | ||
| Q1 24 | 1.0% | 2.2% |
现金转化率ICCCLNTH
| Q4 25 | — | 1.67× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | 3.19× | 1.11× | ||
| Q1 25 | 1.09× | 1.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICCC
暂无分部数据
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
